Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

Data ReadoutpositiveFasedienolPositive

AI Analysis

Summary

Vistagen announced positive topline results from a repeat dose study of fasedienol for acute treatment of social anxiety disorder, demonstrating favorable safety and tolerability consistent with single-dose administration.

Clinical Trial Data

Outcome Details

Repeat dose of fasedienol demonstrated favorable safety and tolerability similar to single dose

Importance:5/10

Sentiment:

0.65

Clinical Trial DataSafetyTolerabilitySocial Anxiety Disorder

Related Companies

$VTGN

Read the original article

Published by GlobeNewswire Clinical Studies on August 6, 2026 12:30 PM

Read Original